E. Crowley

发表

Improved MAGIC gel for higher sensitivity and elemental tissue equivalent 3D dosimetry.

T. Reese, G. El Fakhri, Xuping Zhu, 2009, Medical physics.

Phase 2 Trial of the GPNMB-Targeted Antibody-Drug Conjugate, Glembatumumab Vedotin (CDX-011) in Recurrent Osteosarcoma AOST1521: A Report from the Children’s Oncology Group (COG)

R. Randall, J. Reid, A. Buxton, 2020 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC)

R. Glasspool, D. Dizon, P. Celano, 2008 .

Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study

L. Vitale, R. Gedrich, T. Keler, 2022, Allergy.

Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer.

Ronald C. Chen, D. Ryan, T. Hong, 2012, International journal of radiation oncology, biology, physics.

Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer

R. Glasspool, D. Dizon, P. Celano, 2012, International Journal of Gynecologic Cancer.

Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment.

B. Alexander, D. Ryan, T. Delaney, 2007, International journal of radiation oncology, biology, physics.

A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma

S. Patel, K. Lewis, R. Joseph, 2020, Cancers.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

P. Hwu, M. Sznol, P. Ott, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma.

P. Hwu, M. Sznol, H. Kluger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

J. Bono, J. D. de Bono, S. Engelholm, 2010, British Journal of Cancer.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

A. Stopeck, A. Forero, D. Yardley, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Suzanne F. Jones, L. Hart, J. Bendell, 2014, Journal of Clinical Oncology.

Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.

R. Randall, J. Reid, A. Buxton, 2019, European journal of cancer.

The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria (Cindu)

M. Maurer, T. Hawro, M. Metz, 2022, Journal of Allergy and Clinical Immunology.

Considerations in treatment planning for esophageal cancer.

T. Hong, H. Mamon, J. Killoran, 2007, Seminars in radiation oncology.

In situ vaccine for low-grade lymphoma: Combination of intratumoral Flt3L and poly-ICLC with low-Dose radiotherapy.

S. Kim-Schulze, T. Marron, N. Bhardwaj, 2015 .

Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria

M. Maurer, T. Hawro, M. Metz, 2022, Allergy.

Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).

Suzanne F. Jones, L. Hart, J. Bendell, 2010 .

Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.

P. Hwu, M. Sznol, H. Kluger, 2010 .

Dosimetric comparison of proton and photon three-dimensional, conformal, external beam accelerated partial breast irradiation techniques.

A. Taghian, Jacqueline A. Nyamwanda, T. Delaney, 2006, International journal of radiation oncology, biology, physics.

Abstract P6-10-01: A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study

A. Stopeck, A. Forero, D. Citron, 2012 .

Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer.

A. Niemierko, Jacqueline A. Nyamwanda, D. Ryan, 2015, Practical radiation oncology.

Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma.

P. Hwu, M. Sznol, H. Kluger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC).

L. Hart, J. Bendell, P. Siegel, 2009 .

Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent

J. Reid, A. Buxton, K. Janeway, 2020 .

Modeling Intracranial Second Tumor Risk and Estimates of Clinical Toxicity with Various Radiation Therapy Techniques for Patients with Pituitary Adenoma

A. Niemierko, H. Shih, M. Bussière, 2011, Technology in cancer research & treatment.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors

T. Yap, J. Bono, G. Blumenschein, 2007 .

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

J. Bono, S. Engelholm, R. Penson, 2010, British Journal of Cancer.

Turning a Tumor into a Vaccine Factory: In Situ Vaccination for Low-Grade Lymphoma

T. Marron, N. Bhardwaj, J. Brody, 2014 .